Actively Recruiting
LANDscape MApping of Epitopes and T Cell Receptors for Selected Cancers
Led by University Health Network, Toronto · Updated on 2025-07-02
105
Participants Needed
1
Research Sites
273 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a correlative research project aimed at characterizing the T cell mediated immune responses to hepatocellular carcinoma (HCC), as well as Epstein-Barr virus (EBV)- and human papillomavirus (HPV)-related cancers. This study will enroll approximately 105 patients over 48 months. Of these 105 patients, 30 are EBV-related cancer, 45 are HPV-related cancer, and 30 are HCC. Patients will have blood samples collected one time to identify cancer specific T cells and T cell receptors in their blood. They will also have tissue samples collected one time to study the different types of immune cells, especially the T cells and their receptors. The 105 patients enrolled in this study will be compared to retrospective samples (N=210; 30 from EBV-related cancer cohort, 180 from HPV-related cancer cohort).
CONDITIONS
Official Title
LANDscape MApping of Epitopes and T Cell Receptors for Selected Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with a confirmed diagnosis of EBV-related cancers such as nasopharyngeal cancer
- Patients with HPV-related cancers including squamous cell carcinoma of the head and neck, cervix, vulva, or anal canal; HPV positivity required for head and neck cancers, p16 positivity acceptable; not required for other sites
- For anal canal cancers, late-stage metastatic tissue preferred; early-stage primary tissue acceptable if uncontaminated
- Patients with hepatocellular carcinoma (HCC) having alpha-fetoprotein levels above the upper normal limit
- Patients aged 18 years or older
- Patients who have provided voluntary written informed consent
You will not qualify if you...
- Any condition that may interfere with patient safety, specimen evaluation, or study result interpretation as determined by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
Research Team
K
Kathy Han, MD
CONTACT
K
Kendra Ross
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here